the combined prenatal diagnostic test is consolidated as a method of safe and effective.
9 Congress International of Screening Prenatal.
-the recent evolution of the triple screening test for the detection of Down syndrome to test combined during the first trimester of pregnancy, confirmed his undisputed results improved, avoiding up to one third of invasive procedures that were done and with a greater degree of success in predicting risk.
-international experts will gather in Barcelona to upgrade and find consensus in relation to the Screening Prenatal.
Barcelona, June of 2011- the Prenatal Screening was the subject of analysis by international experts, on 20 and 21 June in Barcelona, in the framework of the 9th International Congress of Prenatal Screening. In this Congress, organized by the International Prenatal Screening Group (IPSG), researchers, specialists in fetal medicine, public health experts, biochemical, geneticists and other professionals discussed the consolidation of the new parameters in the Prenatal Screening of the Catalan model, in contrast to other models in other countries. This screening test has been in the second quarter to the first, in this way is calculated before the risk of Down and other congenital anomalies syndrome.
the before and after the Screening Prenatal.
recently and until the year 2009, the triple screening measured the level of two components through a blood test: alpha-fetoprotein and chorionic gonadotropin (HCG) and was carried out between the week 15-18 of pregnancy. These levels determine the risk of Down syndrome and neural tube defects. Now, the new Screening (combined test) appreciates the plasma protein A (PAPP-A) and the HCG hormone free and takes place during the first quarter, advancing prenatal diagnosis of congenital anomalies, at the time, until the 12 week of pregnancy. Moreover, these new biochemical parameters that determine the Maternal serum has been added the nuchal fold of the fetus, measured by ultrasonography and maternal age. This is a calculation that will end up determining the risk of the fetus of a Down’s syndrome or other chromosomal defects.
the previous Protocol, moreover, established the completion of the screening biochemist to determine the level of risk in pregnant women under the age of 38 years and, indeed, recommended offer more than 37-year-old pregnant women undergo an invasive fetal study procedure directly, such as amniocentesis, for greater certainty, after this age. In the new Protocol, the maternal age itself ceases to be a reason for diagnostic indication invasive, since it has confirmed the validity of the new test, for expectant mothers, at any age. This has refocused this prenatal diagnosis: “the existing criterion that there is a maternal age in which the risk increases significantly is has demonstrated that it is not true.” We now have a better method for the calculation of the prenatal risk. The risk involved in maternal age joins own calculation, but they also have other criteria. Practice of amniocentesis (or coriales biopsies) has declined by a third party. This has much reduced complications arising from these tests invasive, are not free from risks, notably those pregnancies that are confirmed as normal “, explains Dr. Antoni Borrell, Member of the Scientific Committee of the IPSG and Senior consultant in Fetal Medicine from the Hospital ClÃnic of Barcelona.”The number of cases of Down syndrome can be detected in the prenatal period has increased to 90% and we now know, evaluate and confirm the results of these two years of cohabitation with the new Protocol, the combined Test made by reducing the costs of the screening process in Catalonia”, continues Dr. Borrell, also President of the section of ultrasound examinations of the society Catalan of gynaecology and obstetrics.
towards a more accurate, early diagnosis and precise.
frequency of detection of birth defects of the Catalan population, detected during pregnancy or in the first days of life, stood at 3.6 per cent of total births. This means that, in Catalonia, according to current figures from birth, born about 3,000 babies with birth defects. This possibility greatly distressed to pregnant women and their partners. Move this diagnosis only has advantages. In those pregnancies that are confirmed as normal families relieve your distress and those pregnancies that, unfortunately, confirms an anomaly of these characteristics, decision making can be done more early. Thanks to the new Protocol refers to a set of effective recommendations: the woman that go to make a first control of the pregnancy before the 14 weeks of gestation, will receive a screening of the first quarter, which combines two biochemical markers with the ecogrà fica measurement of the nuchal fold, the woman to do so after week 14You will receive a screening of second quarter, updated with four biochemical markers. The detection rate is 90% and 80%, respectively, with a rate of false positive 3 per cent and 5 per cent, respectively.
on the International Prenatal Screening Group (IPSG).
the IPSG is a reference group that has grown from the International Down Syndrome Screening Group (IDSSG) and, today, is an organization with some 1,500 members from 70 countries. The IPSG aims to promote the international collaborative research and exchange of up-to-date information on developments in fetal medicine. A communication network has been created through the Center Coordinator at Leeds but the vocals is the Prenatal Screening Perspectives publication focuses on all aspects of research in screening antenatal.
